Dan Mitchell
Founder at Sequel Venture Partners LLC
Net worth: 2 132 $ as of 29/04/2024
Profile
Daniel J.
Mitchell was the founder of Capital Health Venture Partners, founded in 1986, where he held the title of General Partner from 1986 to 2006.
He is also the founder of Sequel Venture Partners LLC, founded in 1997, where he currently holds the title of Partner.
Mr. Mitchell's current job(s) include being a Director at Plato BioPharma, Inc., a Director at Bolder Surgical LLC since 2019, a Director at ViroCyt, Inc., a Director at Skyland Analytics, Inc., and a Manager at Sequel Venture Partners III LLC.
Mr. Mitchell's former job(s) include being a Director at Gilead Colorado, Inc., a Director at Replidyne, Inc. from 2002 to 2009, an Independent Director at GlobeImmune, Inc. from 2003 to 2016, a Director at IntelliDx, Inc., a Director at Kalypto Medical, Inc., an Independent Director at ARCA biopharma, Inc. from 2014 to 2024, a Principal at First National Bank of Chicago (Illinois) from 1983 to 1986, and a Member at Excel Medical Ventures LLC.
Mr. Mitchell's education history includes an MBA from the University of California, Berkeley and an undergraduate degree from the University of Illinois.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARCA BIOPHARMA, INC.
0.00% | 29/01/2024 | 611 ( 0.00% ) | 2 132 $ | 29/04/2024 |
Dan Mitchell active positions
| Companies | Position | Start |
|---|---|---|
Sequel Venture Partners LLC
 Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | Founder | 31/12/1996 |
ViroCyt, Inc.
 ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | Director/Board Member | - |
| Sequel Venture Partners III LLC | Corporate Officer/Principal | - |
Bolder Surgical LLC
 Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | Director/Board Member | 11/06/2019 |
Plato BioPharma, Inc.
 Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | Director/Board Member | - |
Skyland Analytics, Inc.
 Skyland Analytics, Inc. Packaged SoftwareTechnology Services Skyland Analytics, Inc. provides power of manufacturing informatics software, IT systems and data analytics services. Its services include informatics, risk management and discoverant. The company was founded by Robert M. Di Scipio and is headquartered in Niwot, CO. | Director/Board Member | - |
Former positions of Dan Mitchell
| Companies | Position | End |
|---|---|---|
| ARCA BIOPHARMA, INC. | Director/Board Member | 04/02/2024 |
| GLOBEIMMUNE, INC. | Director/Board Member | 21/11/2016 |
Replidyne, Inc.
 Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Director/Board Member | 26/02/2009 |
| ░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░ ░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Dan Mitchell
| University of Illinois | Undergraduate Degree |
| University of California, Berkeley | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GLOBEIMMUNE, INC. | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| Private companies | 13 |
|---|---|
Sequel Venture Partners LLC
Sequel Venture Partners LLC Investment ManagersFinance Sequel Venture Partners LLC (Sequel Venture Partners) is a venture capital firm founded in 1996 by Kinney Johnson, Daniel Mitchell and Thomas Washing. The firm is headquartered in Boulder, Colorado. | Finance |
Gilead Colorado, Inc.
 Gilead Colorado, Inc. Pharmaceuticals: MajorHealth Technology Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO. | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
| First National Bank of Chicago (Illinois) | Finance |
Excel Medical Ventures LLC
 Excel Medical Ventures LLC Investment ManagersFinance Excel Medical Ventures LLC (Excel Medical Ventures) is a venture capital firm founded in 2004 by Steven R. Gullans. The firm is headquartered in Boston, Massachusetts. | Finance |
IntelliDx, Inc.
 IntelliDx, Inc. Electronic Equipment/InstrumentsElectronic Technology IntelliDx, Inc. develops medical devices. It offers automated ex vivo blood analysis systems that measure the constituents of flowing human blood, and automated blood glucose monitoring systems that measure glucose in hospitalized patients who have abnormally elevated sugar levels. The company was founded in 2000 and is headquartered in Santa Clara, CA. | Electronic Technology |
Kalypto Medical, Inc.
 Kalypto Medical, Inc. Medical SpecialtiesHealth Technology Kalypto Medical, Inc. manufactured medical devices. Its devices were used to treat diabetic leg ulcers. The firm also provided wound-care products. The company was founded in 2006 and was headquartered in Hastings, MN. | Health Technology |
ViroCyt, Inc.
ViroCyt, Inc. Miscellaneous Commercial ServicesCommercial Services ViroCyt, Inc. develops life science instrumentation and assays products for the analysis of viruses and microorganisms. The company was founded in 2012 and is headquartered in Broomfield, CO. | Commercial Services |
Capital Health Venture Partners
 Capital Health Venture Partners Investment ManagersFinance Capital Health Venture Partners is an alternative investment manager. The private company is based in Chicago, IL and has subsidiaries in the United States. The company was founded in 1985 by Daniel J. Mitchell. | Finance |
| Sequel Venture Partners III LLC | |
Bolder Surgical LLC
Bolder Surgical LLC Medical SpecialtiesHealth Technology Bolder Surgical LLC engages in the design, development, and manufacture of surgical devices. Its products include JustRight Vessel Sealing System, JustRight 5mm Stapler, and EcoSac 5mm Tissue Retrieval System. The company was founded by Russell Lindemann, Scott Drake, Dale Schmaltz, Jenifer Kennedy, Patricia Moroney Hoag, David R. Duncan, and Steve Rothenberg on January 22, 2010 and is headquartered in Louisville, CO. | Health Technology |
Plato BioPharma, Inc.
Plato BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Inotiv, Inc., Plato BioPharma, Inc. develops preclinical drug discovery. The company is based in Westminster, CO. Plato BioPharma was acquired by Inotiv, Inc. on October 04, 2021 for $14.76 million. The company was founded in 2010 by Craig F. Plato. Craig F. Plato has been the CEO since 2010. | Health Technology |
Skyland Analytics, Inc.
Skyland Analytics, Inc. Packaged SoftwareTechnology Services Skyland Analytics, Inc. provides power of manufacturing informatics software, IT systems and data analytics services. Its services include informatics, risk management and discoverant. The company was founded by Robert M. Di Scipio and is headquartered in Niwot, CO. | Technology Services |
- Stock Market
- Insiders
- Dan Mitchell